BOCA RATON, FLORIDA--(Marketwire - Aug. 22, 2012) - Allezoe Medical Holdings, Inc. (OTCBB:ALZM) announced today that its SureScreen Medical, Inc. subsidiary has received notice from the European Patent Office that it intends to grant the requested patent for the "see and treat" HPV virus diagnosis and treatment technology SureScreen is developing under an exclusive license, as soon as the remaining procedural steps have been completed. As a result, SureScreen has filed German and French claims translations at the European Patent Office together with the necessary request for further processing of the patent application for the technology. With completion of these actions, all of the procedural steps for the grant of the patent now have been undertaken, and the application has been placed in the queue for publication as a granted patent. The US patent application remains under review by the US Patent & Trademark Office.

SureScreen is developing the "see and treat" technology under a licensing agreement that grants it exclusive worldwide rights to develop, seek patent protection for, and market the technology. The "see and treat" technology aims to allow healthcare professionals to detect and treat the most common sexually transmitted infection, and a cause of cervical cancer, Human Papillomavirus (HPV), in a single visit. According to Caroline Pinnell, President and COO of ALZM and Chairman of the SureScreen subsidiary: "We are pleased and excited about the continued development of SureScreen's "see and treat" technology and its potential impact on the health of women worldwide. Its development, along with the recently-announced acquisition of OVWatch, is another boost to the growing line up of Allezoe Medical subsidiaries' cutting edge technologies."

FORWARD LOOKING STATEMENT

Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM or its subsidiaries may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and includes, without limitation, statements regarding ALZM's plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. These risks and others are included from time to time in documents we file with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on our future results. Accordingly, you should not place undue reliance on these forward-looking statements. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company undertakes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the Company. The Company's SEC filings are available at [ http://www.sec.gov ].